Aquestive Therapeutics Inc.
AQST | NASDAQ
$4.78
+$0.17 (+3.69%)
At close: Sep 21, 2026, 4:00 PM ET
$4.74
-$0.04 (-0.84%)
After-hours:
Sep 21, 2026, 7:59 PM ET
Market Data
Market Cap $578.4M
Enterprise Value $560.24M
Beta 1.47
Average Volume 2.38M
Shares Outstanding (Diluted) 124.99M
Shares Change YoY 25.84%
Institutional Ownership 58.74%
Exchange NASDAQ
ISIN US03843E1047
Price Performance
Price Change 1M 2.4%
Price Change 3M -5.0%
Price Change 6M 13.5%
Price Change YTD -25.9%
Price Change 1Y -7.5%
Price Change 3Y 202.5%
Price Change 5Y 10.4%
1M CAGR (ann.) 17.6%
1Y CAGR (ann.) -4.5%
5Y CAGR (ann.) 0.8%
All-Time CAGR -14.2%
Valuation
PE Ratio -7.35
Forward PE N/A
PEG Ratio -6.32
Forward PEG -3.92
PS Ratio 11.09
Forward PS 8.80
PB Ratio -10.60
P/FCF Ratio -13.05
P/Adj. FCF Ratio -10.84
P/OCF Ratio -13.28
EV/Sales 10.36
EV/EBIT -9.05
EV/EBITDA -9.14
EV/FCF -12.19
Earnings Yield -13.6%
FCF Yield -7.7%
Adj. FCF Yield -9.2%
Financial Health
Net Cash $47.84M
Total Debt $59M
Cash & Short-Term Investments $98.49M
Total Assets $132.1M
Current Ratio 7.19
Quick Ratio 6.74
Debt / Equity Ratio -1.04
Debt / EBITDA -0.96
Debt / FCF -1.28
OCF / Debt -0.77
Interest Coverage -3.23
Altman Z-Score -3.44
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 67.0%
Operating Profit Margin -97.5%
EBITDA Margin -113.3%
Net Profit Margin -144.6%
FCF Margin -85.0%
Adj. FCF Margin -102.3%
SBC / Revenue 17.3%
SBC Impact (per share) -20.4%
Returns
Return on Assets -59.2%
Return on Equity 243.7%
Return on Invested Capital -45.3%
Return on Capital Employed -45.6%
Return on Tangible Assets -59.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 5.2%
Revenue CAGR 5Y 5.3%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -26.5%
EPS CAGR 5Y 28.0%
EPS CAGR 10Y N/A
FCF CAGR 3Y -26.1%
FCF CAGR 5Y -24.0%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 10
EPS Growth Next 3Y 32.3%
Revenue Growth Next 3Y 51.4%
Earnings Date Nov 3, 2026
EPS Estimate (next Q) -$0.10
EPS Growth Est (next Q) -28.6%
Revenue Est (next Q) $11.02M
Revenue Growth Est (next Q) -14.0%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $11
Price Target Upside 130.1%
Cash Flow
Operating Cash Flow $-45.37M
Free Cash Flow $-45.95M
Adj. Free Cash Flow $-55.32M
FCF Per Share -$0.37
OCF Per Share -$0.36
OCF/S Ratio -83.9%
Income Statement
Revenue $54.09M
Gross Profit $36.26M
Operating Income $-52.75M
EBITDA $-61.27M
Net Income $-78.23M
EPS (Diluted) -$0.65
Revenue / Employee $367.94K
Profit / Employee $-532.16K
Employees 147
Add to Watchlist
Select watchlists to add or remove AQST